drugset / Trial / NCT05405387

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

NCT05405387

Phase 2 Recruiting 120 enrolled University of Utah
RandomizedSequentialQuadruple-blindTreatment

Summary

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

Timeline

Start
2023-05-03
Primary completion
2026-12
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 3 mg Oral